文献速递糖尿病

在2型糖尿病患者基础-餐时方案中比较超速赖脯胰岛素与赖脯胰岛素的随机双盲临床试验:PRONTO-T2D

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
PubMed 文献 · Diabetes Care · 2020-07-02

PRONTO-T2D是一项3期、达标治疗、双盲26周研究,2型糖尿病患者经8周基础胰岛素优化后随机接受超速赖脯胰岛素(URLi,n=336)或赖脯胰岛素(n=337)餐前0-2分钟注射。主要终点HbA1c变化证实非劣效(估计治疗差异0.06%,95%CI -0.05; 0.16),URLi在控制餐后1小时和2小时血糖 excursions 方面优于赖脯胰岛素。

要点

  • URLi组HbA1c平均变化-0.38%,赖脯胰岛素组-0.43%,估计治疗差异0.06%(95%CI -0.05; 0.16),非劣效成立。
  • URLi在控制餐后1小时血糖 excursions 方面优于赖脯胰岛素,估计治疗差异-0.66 mmol/L(95%CI -1.01, -0.30)。
  • URLi在控制餐后2小时血糖 excursions 方面优于赖脯胰岛素,估计治疗差异-0.96 mmol/L(95%CI -1.41, -0.52)。

核心结论

  • 在基础-餐时方案中,URLi与赖脯胰岛素相比,HbA1c非劣效成立,且在2型糖尿病患者餐后血糖控制方面优于赖脯胰岛素。

研究设计与样本

  • 3期、达标治疗、双盲26周研究;经8周基础胰岛素甘精胰岛素或德谷胰岛素联合餐时赖脯胰岛素优化后,患者随机接受盲法URLi(n=336)或赖脯胰岛素(n=337),餐前0-2分钟注射。

主要发现

  • URLi组HbA1c平均变化-0.38%,赖脯胰岛素组-0.43%,估计治疗差异0.06%(95%CI -0.05; 0.16),非劣效成立。
  • 治疗结束时HbA1c分别为URLi组6.92%和赖脯胰岛素组6.86%。
  • 餐后1小时血糖 excursions 估计治疗差异为-0.66 mmol/L(95%CI -1.01, -0.30),餐后2小时为-0.96 mmol/L(95%CI -1.41, -0.52),均支持URLi优于赖脯胰岛素。
  • URLi治疗在餐后0.5至4.0小时期间餐后血糖 excursions 显著更低。
  • 严重或记录的低血糖(<3.0 mmol/L)发生率方面无显著治疗差异,总体治疗中出现的不良事件发生率两组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in patients with type 2 diabetes on a basal-bolus insulin regimen. RESEARCH DESIGN AND METHODS: This was a phase 3, treat-to-target, double-blind 26-week study. After an 8-week lead-in to optimize basal insulin glargine or degludec in combination with prandial lispro treatment, patients were randomized to blinded URLi (n = 336) or lispro (n = 337) injected 0-2 min prior to meals. Patients could continue metformin and/or a sodium-glucose cotransporter 2 inhibitor. The primary end point was change in HbA1c from baseline to 26 weeks (noninferiority margin 0.4%), with multiplicity-adjusted objectives for postprandial glucose (PPG) excursions during a standardized meal test. RESULTS: HbA1c improved for both URLi and lispro, and noninferiority was confirmed: estimated treatment difference (ETD) 0.06% (95% CI -0.05; 0.16). Mean change in HbA1c was -0.38% for URLi and -0.43% for lispro, with an end-of-treatment HbA1c of 6.92% and 6.86%, respectively. URLi was superior to lispro in controlling 1- and 2-h PPG excursions: 1-h ETD, -0.66 mmol/L (95% CI -1.01, -0.30); 2-h ETD, -0.96 mmol/L (-1.41, -0.52). Significantly lower PPG excursions were evident from 0.5 to 4.0 h postmeal with URLi treatment. There were no significant treatment differences in rates of severe or documented hypoglycemia (<3.0 mmol/L). Incidence of overall treatment-emergent adverse events was similar between treatments. CONCLUSIONS: URLi compared with lispro in a basal-bolus regimen was confirmed to be noninferior for HbA1c and superior to lispro for PPG control in patients with type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Blevins T, Zhang Q, Frias JP, et al. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D. Diabetes Care. 2020. PMID: 32616612. doi:10.2337/dc19-2550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。